Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Researchers from University of Southampton, Cancer Sciences Division describe findings in vaccines
May 27th, 2008
Current study results from the report, 'Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells,' have been published. "Activation of invariant NK T (iNKT) cells with the glycolipid alpha-galactosylceramide promotes CD8(+) cytotoxic T cell responses, a property that has been used to enhance the efficacy of antitumor vaccines. Using chimeric mice, we now show that the adjuvant properties of iNKT cells require that CD40 triggering and Ag presentation to CD8(+) T cells occur on the same APCs," scientists writing in the Journal of Immunology report. "We demonstrate that injection of alpha-galactosylceramide triggers...
Source: Cancer Weekly (2008-05-27)
|
